Aligos Therapeutics, Inc.
ALGS
$10.14
$0.303.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 965.00K | 311.00K | 629.00K | 1.27M | 1.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 965.00K | 311.00K | 629.00K | 1.27M | 1.06M |
| Cost of Revenue | 13.98M | 14.50M | 16.03M | 16.77M | 21.10M |
| Gross Profit | -13.01M | -14.19M | -15.40M | -15.51M | -20.04M |
| SG&A Expenses | 5.56M | 5.05M | 5.16M | 4.63M | 6.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.53M | 19.55M | 21.19M | 21.40M | 27.48M |
| Operating Income | -18.57M | -19.24M | -20.56M | -20.13M | -26.41M |
| Income Before Tax | -15.68M | 43.13M | -82.12M | -19.17M | 5.25M |
| Income Tax Expenses | 185.00K | 43.00K | 27.00K | 91.00K | 189.00K |
| Earnings from Continuing Operations | -15.86M | 43.09M | -82.15M | -19.26M | 5.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.86M | 43.09M | -82.15M | -19.26M | 5.06M |
| EBIT | -18.57M | -19.24M | -20.56M | -20.13M | -26.41M |
| EBITDA | -18.31M | -19.05M | -20.32M | -19.88M | -26.16M |
| EPS Basic | -1.53 | 5.12 | -13.08 | -3.07 | 0.81 |
| Normalized Basic EPS | -0.95 | 3.21 | -8.17 | -1.91 | 0.52 |
| EPS Diluted | -1.53 | -2.11 | -13.08 | -3.07 | 0.81 |
| Normalized Diluted EPS | -0.95 | 3.10 | -8.17 | -1.91 | 0.52 |
| Average Basic Shares Outstanding | 10.35M | 8.41M | 6.28M | 6.27M | 6.26M |
| Average Diluted Shares Outstanding | 10.35M | 8.71M | 6.28M | 6.27M | 6.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |